ISPIRE TECHNOLOGY INC (ISPR)

US46501C1009 - Common Stock

5.73  -0.38 (-6.22%)

Fundamental Rating

3

Taking everything into account, ISPR scores 3 out of 10 in our fundamental rating. ISPR was compared to 8 industry peers in the Tobacco industry. ISPR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ISPR is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ISPR has reported negative net income.
In the past year ISPR has reported a negative cash flow from operations.

1.2 Ratios

The Return On Assets of ISPR (-14.72%) is worse than 75.00% of its industry peers.
ISPR has a Return On Equity (-61.82%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -14.72%
ROE -61.82%
ROIC N/A
ROA(3y)-6.85%
ROA(5y)N/A
ROE(3y)-25.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ISPR has a worse Gross Margin (20.71%) than 62.50% of its industry peers.
In the last couple of years the Gross Margin of ISPR has grown nicely.
ISPR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.08%
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

ISPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
ISPR has more shares outstanding than it did 1 year ago.
ISPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 2.62 indicates that ISPR is not a great score, but indicates only limited risk for bankruptcy at the moment.
ISPR's Altman-Z score of 2.62 is on the low side compared to the rest of the industry. ISPR is outperformed by 62.50% of its industry peers.
There is no outstanding debt for ISPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.62
ROIC/WACCN/A
WACC9.16%

2.3 Liquidity

ISPR has a Current Ratio of 1.13. This is a normal value and indicates that ISPR is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ISPR (1.13) is better than 62.50% of its industry peers.
ISPR has a Quick Ratio of 1.05. This is a normal value and indicates that ISPR is financially healthy and should not expect problems in meeting its short term obligations.
ISPR has a better Quick ratio (1.05) than 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.05

More info and screens

6

3. Growth

3.1 Past

ISPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -172.56%.
ISPR shows a decrease in Revenue. In the last year, the revenue decreased by -6.37%.
The Revenue has been growing by 33.80% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-172.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-233.33%
Revenue 1Y (TTM)-6.37%
Revenue growth 3Y33.8%
Revenue growth 5YN/A
Sales Q2Q%-8.23%

3.2 Future

ISPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.80% yearly.
ISPR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 47.43% yearly.
EPS Next Y11.86%
EPS Next 2Y43.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year23.81%
Revenue Next 2Y47.43%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ISPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 280.88, which means the current valuation is very expensive for ISPR.
ISPR's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. ISPR is more expensive than 62.50% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.99, ISPR is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 280.88

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ISPR's earnings are expected to grow with 43.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.8%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ISPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ISPIRE TECHNOLOGY INC

NASDAQ:ISPR (12/24/2024, 8:21:44 PM)

5.73

-0.38 (-6.22%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)11-11 2024-11-11/bmo
Earnings (Next)02-19 2025-02-19/bmo
Inst Owners7.33%
Inst Owner Change23.47%
Ins Owners4.8%
Ins Owner Change41.54%
Market Cap324.60M
Analysts80
Price Target9.69 (69.11%)
Short Float %3.87%
Short Ratio7.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.38%
Min EPS beat(2)-63.4%
Max EPS beat(2)34.64%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-9.22%
Min Revenue beat(2)-25.34%
Max Revenue beat(2)6.9%
Revenue beat(4)1
Avg Revenue beat(4)-17.16%
Min Revenue beat(4)-35.33%
Max Revenue beat(4)6.9%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-100%
EPS NQ rev (3m)-180%
EPS NY rev (1m)-173.68%
EPS NY rev (3m)-116.67%
Revenue NQ rev (1m)-19.5%
Revenue NQ rev (3m)-9.83%
Revenue NY rev (1m)-23.57%
Revenue NY rev (3m)-14.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 280.88
P/S 2.19
P/FCF N/A
P/OCF N/A
P/B 10.57
P/tB 11.31
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)0.02
Fwd EY0.36%
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS2.62
BVpS0.54
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.72%
ROE -61.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.71%
FCFM N/A
ROA(3y)-6.85%
ROA(5y)N/A
ROE(3y)-25.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.08%
GM growth 5YN/A
F-Score3
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 150.69%
Cap/Sales 2.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.05
Altman-Z 2.62
F-Score3
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)1179.72%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-172.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-233.33%
EPS Next Y11.86%
EPS Next 2Y43.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.37%
Revenue growth 3Y33.8%
Revenue growth 5YN/A
Sales Q2Q%-8.23%
Revenue Next Year23.81%
Revenue Next 2Y47.43%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-287.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-126.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-116.45%
OCF growth 3YN/A
OCF growth 5YN/A